Search results for "SVI"

showing 10 items of 4456 documents

Intrasinusoidal HHV8-EBV–Positive Large B-Cell Lymphoma With Features of Germinotropic Lymphoproliferative Disorder

2020

Germinotropic lymphoproliferative disorder (GLPD) is a poorly characterized lymphoproliferative entity, recently included in the World Health Organization classification of hematolymphoid neoplasms. The histological pattern of this disease comprises monotypic plasmablasts that involve the germinal centers of the lymphoid follicles (germinotrophism), forming confluent aggregates positive for both human herpes virus type 8 (HHV8) and Epstein-Barr virus. Currently, after 17 years of its first description, only 18 cases have been reported. In this article, we describe a case of a GLPD presenting in an immunocompetent 79-year-old woman with localized axillary lymphadenopathy, showing a prominen…

0301 basic medicineEpstein-Barr Virus InfectionsHerpesvirus 4 HumanPathologymedicine.medical_specialtyLymphoma B-Cellmedicine.disease_causePathology and Forensic Medicine03 medical and health sciences0302 clinical medicinemedicineAxillary LymphadenopathyHumansB-cell lymphomaAnaplastic large-cell lymphomaAgedbusiness.industryGerminal centerHerpesviridae Infectionsmedicine.diseaseEpstein–Barr virusLymphoproliferative DisordersLymphoma030104 developmental biologyPleomorphism (cytology)030220 oncology & carcinogenesisHerpesvirus 8 HumanFemaleSurgeryLymph NodesAnatomyDifferential diagnosisbusinessInternational Journal of Surgical Pathology
researchProduct

Risk of Classic Kaposi Sarcoma With Combinations of Killer Immunoglobulin-Like Receptor and Human Leukocyte Antigen Loci: A Population-Based Case-con…

2015

BACKGROUND Kaposi sarcoma (KS) is a complication of KS-associated herpesvirus (KSHV) infection. Other oncogenic viral infections and malignancies are associated with certain HLA alleles and their natural killer (NK) cell immunoglobulin-like receptor (KIR) ligands. We tested whether HLA-KIR influences the risk of KSHV infection or KS. METHODS In population-based case-control studies, we compared HLA class I and KIR gene frequencies in 250 classic (non-AIDS) KS cases, 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls composing discovery and validation cohorts. Logistic regression was used to calculate sex- and age-adjusted odds ratios (ORs) and 95% confidence intervals. RESUL…

0301 basic medicineGenotypevirusescase-control studyPopulationchemical and pharmacologic phenomenaHuman leukocyte antigenBiologyLymphocyte ActivationSettore MED/42 - Igiene Generale E ApplicataMajor Articles and Brief Reports03 medical and health sciencesReceptors KIRnatural killer–cell immunoglobulin-like receptorsHLA AntigensRisk FactorsSeroepidemiologic Studieshuman leukocyte antigenGenotypeotorhinolaryngologic diseasesHLA-B AntigensHumansImmunology and AllergySeroprevalenceGenetic Predisposition to Diseasehuman geneticeducationSarcoma Kaposieducation.field_of_studyClassic Kaposi SarcomaCase-control studyvirus diseasesKaposi sarcomaOdds ratiomajor histocompatibility complex030104 developmental biologyInfectious DiseasesGene Expression RegulationItalyCase-Control StudiesItaly; Kaposi sarcoma; case-control study; human genetics; human leukocyte antigens; major histocompatibility complex; natural killer–cell immunoglobulin-like receptorsHerpesvirus 8 HumanImmunologyJournal of Infectious Diseases
researchProduct

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine

2015

The abietane-type diterpenoid (+)-ferruginol (1), a bioactive compound isolated from several plants, has attracted much attention as consequence of its pharmacological properties, which includes antibacterial, antifungal, antimicrobial, cardioprotective, anti-oxidative, anti-plasmodial, leishmanicidal, anti-ulcerogenic, anti-inflammatory and antitumor actions. In this study, we report on the antiviral evaluation of ferruginol (1) and several analogues synthesized from commercial (+)-dehydroabietylamine. Thus, the activity against Human Herpesvirus type 1, Human Herpesvirus type 2 and Dengue Virus type 2, was studied. Two ferruginol analogues showed high antiviral selectivity index and reduc…

0301 basic medicineHerpesvirus 2 HumanDehydroabietylamineHerpesvirus 1 HumanMicrobial Sensitivity TestsDengue virusmedicine.disease_causeAntiviral AgentsArticleDengue feverDengueStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundDrug DiscoverymedicineHumansStructure–activity relationshipAntiviralFerruginolAbietanePharmacologyDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryStereoisomerismGeneral MedicineDengue VirusHerpesmedicine.diseaseAntimicrobialBioactive compoundFerruginol030104 developmental biologyBiochemistryAbietanesAbietaneDiterpeneDiterpeneEuropean Journal of Medicinal Chemistry
researchProduct

Linear biocompatible glyco-polyamidoamines as dual action mode virus infection inhibitors with potential as broad-spectrum microbicides for sexually …

2016

AbstractThe initial steps of viral infections are mediated by interactions between viral proteins and cellular receptors. Blocking the latter with high-affinity ligands may inhibit infection. DC-SIGN, a C-type lectin receptor expressed by immature dendritic cells and macrophages, mediates human immunodeficiency virus (HIV) infection by recognizing mannose clusters on the HIV-1 gp120 envelope glycoprotein. Mannosylated glycodendrimers act as HIV entry inhibitors thanks to their ability to block this receptor. Previously, an amphoteric, but prevailingly cationic polyamidoamine named AGMA1 proved effective as infection inhibitor for several heparan sulfate proteoglycan-dependent viruses, such …

0301 basic medicineHerpesvirus 2 HumanSexually Transmitted DiseasesMannoseBiocompatible MaterialsHIV Infections010402 general chemistrymedicine.disease_causeAntiviral Agents01 natural sciencesantivirals polymers glyco-conjugates click-chemistry HIV HPVArticleVirus03 medical and health scienceschemistry.chemical_compoundPolyaminesmedicineHumansReceptorchemistry.chemical_classificationHuman papillomavirus 16MultidisciplinarybiologyLectinHeparan sulfateVirology0104 chemical sciencesMolecular WeightMicrobicides for sexually transmitted diseases030104 developmental biologyHerpes simplex viruschemistryHIV-1biology.proteinBiological AssayGlycoproteinMannoseHeLa CellsScientific Reports
researchProduct

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

2018

Background & aims AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with interferon-free regimens. However, it remains unclear how to respond to a detectable or even quantifiable HCV RNA result. The aim of this study was to analyse the frequency and predictive value of detectable and quantifiable HCV RNA results at the EOT in patients with HCV genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort. Methods A retrospective analysis of the DHC-R (Deutsches Hepatitis C-Register, German Hepatitis C-Registry) coh…

0301 basic medicineLedipasvirMalemedicine.medical_specialtySofosbuvirSustained Virologic ResponseHepatitis C virusMedizinHepacivirusmedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineGermanyRibavirinMedicineHumansClinical significanceRegistriesRetrospective StudiesHepatitisFluorenesHepatologybusiness.industryRibavirinvirus diseasesHepatitis CViral Loadmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologychemistryRNA Viral030211 gastroenterology & hepatologyBenzimidazolesFemaleSofosbuvirbusinessUridine MonophosphateViral loadmedicine.drug
researchProduct

Protective and causative killer Ig-like receptor (KIR) and metalloproteinase genetic patterns associated with Herpes simplex virus 1 (HSV-1) encephal…

2020

Abstract Background The cerebral innate immune system has a critical role in control processes of viral replication in the brain after primary infactivo and immunologic disregulation and inflammation has been reported as a primary determinant of pathogenesis and prognosis of subsequent HSV-1 related encephalitis (HSE). Interaction linking LTR3-activated DCs is also represented by the killer Ig-like receptor (KIR) + pathways on NK cells. Only a few studies analyzed the role of of MMP-9 activity regulating genetic polymorphism on clinical outcome of viral infections. Susceptibility to symptomatic encephalitis depends on SNC viral invasion and BBB disruption. We hypothesize that certain KIR ge…

0301 basic medicineMaleImmunologyHuman leukocyte antigenHerpesvirus 1 Humanmedicine.disease_causePathogenesisCohort StudiesMetalloprotease03 medical and health sciences0302 clinical medicineReceptors KIRHLA AntigensEncephalitiGenotypemedicineImmunology and AllergyHumansEncephalitis ViralHLA AntigenAllele frequencyAgedbusiness.industryHaplotypeHerpes SimplexMiddle Agedmedicine.diseaseHSV-1KIR030104 developmental biologyHerpes simplex virusNeurologyViral replicationMatrix Metalloproteinase 9ImmunologyMetalloproteasesFemaleNeurology (clinical)Cohort StudiebusinessInfectionMMP-9030217 neurology & neurosurgeryEncephalitis
researchProduct

Myeloid Cells Restrict MCMV and Drive Stress- Induced Extramedullary Hematopoiesis through STAT1

2019

Cytomegalovirus (CMV) has a high prevalence worldwide, is often fatal for immunocompromised patients, and causes bone marrow suppression. Deficiency of signal transducer and activator of transcription 1 (STAT1) results in severely impaired antiviral immunity. We have used cell- type restricted deletion of Stat1 to determine the importance of myeloid cell activity for the defense against murine CMV (MCMV). We show that myeloid STAT1 limits MCMV burden and infection- associated pathology in the spleen but does not affect ultimate clearance of infection. Unexpectedly, we found an essential role of myeloid STAT1 in the induction of extramedullary hematopoiesis (EMH). The EMH- promoting function…

0301 basic medicineMaleMuromegalovirusMyeloidIFN-II receptorReceptor Interferon alpha-betamonocytes signal transducer and activator of transcription Herpesviridae IFN-I receptor IFN-II receptor L-27 receptor TLR9 agonistmedicine.disease_causeVirus Replication0302 clinical medicineTLR9 agonistMyeloid CellsSTAT1Cells CulturedHerpesviridaeReceptors Interferonsignal transducer and activator of transcriptionvirus diseasesIL-27 receptorHerpesviridae InfectionsExtramedullary hematopoiesisKiller Cells NaturalHaematopoiesismedicine.anatomical_structureSTAT1 Transcription FactorBone marrow suppressionHematopoiesis ExtramedullaryFemalemonocytesBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.SpleenBiologyGeneral Biochemistry Genetics and Molecular BiologyHerpesviridaeArticle03 medical and health sciencesStress PhysiologicalmedicineAnimalsBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Receptors Interleukinmedicine.diseaseMice Inbred C57BL030104 developmental biologyImmunologySTAT proteinbiology.protein030217 neurology & neurosurgeryGene DeletionSpleenIFN-I receptor
researchProduct

Comparison of the artus Epstein-Barr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell…

2017

The ability of the artus Epstein-Barr virus (EBV) PCR kit and the Abbott RealTime EBV PCR assay to detect and quantify plasma EBV DNAemia was compared. The agreement between these assays was 95.8%. The EBV DNA loads measured by the two assays significantly correlated (P=< 0.0001).

0301 basic medicineMicrobiology (medical)AdultEpstein-Barr Virus InfectionsHerpesvirus 4 Human030106 microbiologyPcr assayBiologymedicine.disease_causeVirus03 medical and health sciencesPlasmahemic and lymphatic diseasesmedicineHumansTransplantation HomologousGeneral MedicineViral LoadEpstein–Barr virusVirologyTransplant Recipients030104 developmental biologyInfectious DiseasesReal-time polymerase chain reactionMolecular Diagnostic TechniquesDNA ViralStem cellStem Cell TransplantationDiagnostic microbiology and infectious disease
researchProduct

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct